Fipexide

From Self-sufficiency
Revision as of 16:38, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Fipexide
File:Fipexide.png
Systematic (IUPAC) name
1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-
2-(4-chlorophenoxy)ethanone
Identifiers
CAS Number 34161-24-5
ATC code N06BX05 (WHO)
PubChem CID 3351
Chemical data
Formula C20H21ClN2O4
Molar mass 388.845 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Fipexide (Attentil, Vigilor) is a psychoactive drug of the piperazine chemical class which was developed in Italy in 1983.[1] It was used as a nootropic drug in Italy and France, mainly for the treatment of senile dementia,[2] but is no longer in common use due to the occurrence of rare adverse drug reactions including fever[3] and hepatitis. Fipexide is similar in action to other nootropic drugs such as piracetam and is structurally similar to another more well-known nootropic, centrophenoxine. Chemically, it is an amide union of parachlorophenoxyacetate and methylenedioxybenzylpiperazine, and notably, has been shown to metabolize to the latter, which plays a significant role in its effects.

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


it:Fipexide
  1. Missale C, Pasinetti G, Govoni S, Spano PF, Trabucchi M. Fipexide: a new drug for the regulation of dopaminergic system at the macromolecular level. Bollettino Chimico Farmaceutico. 1983 Feb;122(2):79-85.
  2. Bompani R, Scali G. Fipexide, an effective cognition activator in the elderly: a placebo-controlled, double-blind clinical trial. Current Medical Research and Opinion. 1986;10(2):99-106.
  3. Guy C, Blay N, Rousset H, Fardeau V, Ollagnier M. Fever caused by fipexide. Evaluation of the national pharmacovigilance survey. Therapie. 1990 Sep-Oct;45(5):429-31.